Search results

  1. Chronic pain: oral ketamine (ESUOM27)

    Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making

  2. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

  3. Scleroderma: oral mycophenolate (ESUOM32)

    Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

  4. First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)

    The key therapeutic topic first-choice antidepressant use in adults with depression or generalised anxiety disorder has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .

  5. Digital ulcers: sildenafil (ESUOM42)

    Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

  6. Type 2 diabetes: dulaglutide (ESNM59)

    Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

  7. Minocycline (KTT11)

    The key therapeutic topic minocycline has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .

  8. Laxatives (KTT1)

    The key therapeutic topic laxatives has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .

  9. Gouty arthritis: canakinumab (ESNM23)

    Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

  10. Type 2 diabetes: lixisenatide (ESNM26)

    Summary of the evidence on lixisenatide (glucagon-like peptide-1 [GLP-1] mimetic) for treating type 2 diabetes to inform local NHS planning and decision-making

  11. Pulmonary sarcoidosis: infliximab (ES2)

    Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

  12. Type 2 diabetes: alogliptin (ESNM20)

    Summary of the evidence on alogliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor) for type 2 diabetes to inform local NHS planning and decision-making